Transfusion-related Acute Lung Injury: a Prospective Cohort Study in Critically Ill Children

NCT ID: NCT02613377

Last Updated: 2023-04-18

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 717 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-01-31
• Study Completion Date: 2021-12-31

Brief Summary

Transfusions cause more adverse events in children than in adults. Patients in pediatric intensive care units (PICU) are particularly exposed to transfusions of plasma-rich blood products (red blood cell (RBC), plasma and platelets) and the risk of adverse events after a transfusion is particularly high in this vulnerable population. Transfusion-related acute lung injury (TRALI), an acute inflammation of the lungs that impairs gas exchange leading to acute respiratory failure, is one of the 2 most deadly transfusion complications in the general population. There is limited evidence on TRALI incidence and impact in critically ill children. This reduces the awareness of PICU team for this complication, and makes the decision process to transfuse particularly difficult. Moreover, acute lung injury is highly prevalent in critically ill children. It is therefore complex to ascertain if the high frequency of respiratory deteriorations observed after a transfusion in PICU is explained by the transfusion itself or by the evolution of the patient's critical illness.

The investigators will conduct a cohort study of consecutive transfused critically ill children, with a control group of matched non-transfused children. The primary objective is to determine if transfusion of RBC, plasma and/or platelets in PICU is an independent risk factor of TRALI, and to compare the respiratory evolution in the two matched (transfused and non-transfused) groups. The secondary objectives will include the determination of the incidence rate, risk factors and clinical impact of TRALI in transfused PICU patients. The investigators will study both "classic TRALI" and "delayed TRALI".

Detailed Description

Study Design This prospective cohort study will include all consecutive transfused patients admitted to the participating PICUs over a one-year period and a control group of matched non-transfused patients. The primary objectives will be assessed using the complete cohort of transfused and non-transfused patients. Secondary objectives will be studied in transfused patients.

Outcomes The primary outcome measure is TRALI (definite, probable, and delayed TRALI) as defined in section. In the non-transfused patients, the definition of Acute Lung Injury will be the same as the one used as a criterion for defining TRALI, and the observation period will be a similar 72-h period, starting at the same time zero.

Primary Objectives

• Objective #1a: to determine if the transfusion of RBC, plasma or platelets is an independent risk factor of TRALI in critically ill children.
• Objective #1b: to compare the progression of the respiratory function, in particular the SpO2/FiO2 ratio, in transfused and non-transfused PICU patients.

Secondary Objectives

• Objective #2.a : To determine the incidence rate of classic (definite or probable) TRALI and of delayed TRALI in transfused PICU patients.
• Objective #2.b : To characterize the risk factors of classic (definite or probable) TRALI and of delayed TRALI in transfused PICU patients.
• Objective #2.c : To compare the progression of respiratory parameters after a 1st transfusion in PICU patients with classic TRALI, delayed TRALI, and without TRALI.
• Objective #2.d : To compare the outcomes of transfused PICU patients with and without classic (definite or probable) TRALI and delayed TRALI.
• Objective #2.e : To describe the inflammatory profile of PICU patients with definite, probable, and delayed TRALI.

Conditions

Acute Lung Injury

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Transfused critically ill children

Any infusion of RBC, plasma or platelets will be considered a transfusion.

Blood transfusion

Intervention Type: OTHER

Non-transfused critically ill children

For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).

No interventions assigned to this group

Interventions

Blood transfusion

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• admission to the PICU

Exclusion Criteria

• gestational age < 40 weeks at entry into PICU
• post-term age less than 3 days or more than 18 years at PICU admission
• patients on extra-corporeal membrane oxygenation or ventricular assist device
• pregnancy present at entry into the PICU
• admission to PICU just after labor

• Minimum Eligible Age: 3 Days
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Canadian Blood Services

OTHER

Sponsor Role: collaborator

St. Justine's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Dr Guillaume Emeriaud

MD, PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Guillaume Emeriaud, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

St. Justine's Hospital

Locations

Alberta Children's Hospital

Calgary, Alberta, Canada

Children's Hospital of Eastern Ontario

Ottawa, Ontario, Canada

St. Justine's Hospital

Montreal, Quebec, Canada

Montreal Children's Hospital

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

CHUSJ-MP-21-2016-1070

Identifier Type: -

Identifier Source: org_study_id